Study of 211At-MABG for Advanced Neuroendocrine Cancers
This study is testing a treatment called 211At-MABG for adults with advanced neuroendocrine cancers, including pheochromocytoma, paraganglioma, neuroendocrine tumors, medullary thyroid cancer, and bronchial carcinoid. This treatment uses a radioactive substance (Astatine-211) attached to a special molecule (meta-astatobenzylguanidine) to target cancer cells. You might be able to join if your cancer is advanced and hasn't responded to, or you can't receive, standard treatments. You also need to have MIBG-avid disease, meaning your tumors show up on a special imaging scan (MIBG imaging). The main goal of this study is to see if the treatment is safe and practical to give, which will be evaluated over 4 weeks. The study is currently unclear on its recruitment status and plans to enroll 16 participants.
- Study design
- This is a Phase 1 dose-escalation study, meaning different doses of 211At-MABG will be tested to find the safest and most effective amount. It will follow a standard 3+3 design with an expansion cohort.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoints for evaluating feasibility are measured at 4 weeks after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
211At-MABG in Adults With Advanced Neuroendocrine Cancers
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Vivek Narayan, MD, MS · PRINCIPAL_INVESTIGATOR · University of Pennsylvania
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Evaluate overall study feasibility4 weeks
Proportion of intended 211At-MABG fractionated doses that are successfully administered within the protocol-defined window (at the overall study level).
- Evaluate study feasibility overall study feasibility assessed for operational issues versus treatment-related adverse events.4 weeks
Proportion of fractionated dose administrations either delayed and/or omitted due to operational issues (i.e. insufficient/delayed synthesis) versus treatment-related adverse events (at the overall study level).